Sinopharm Tech Holdings Limited filed its resubmitted Monthly Return for the period ended 31 August 2026, confirming a stable share base and compliance with Hong Kong Stock Exchange public-float requirements.

• Authorised capital unchanged The authorised share capital remains at HKD 200.00 million, divided into 12.80 billion ordinary shares and 3.20 billion non-voting convertible preference shares, each with a par value of HKD 0.0125.

• Issued share capital steady Ordinary shares in issue stayed at 633.69 million, while issued convertible preference shares (CPS) held at 1.48 billion. No treasury shares were held or cancelled during the month.

• Public float compliance Public shareholders owned 24.95% of the ordinary share class as at 31 August 2026, satisfying the minimum float requirement under GEM Rule 17.37D(1).

• Equity incentive position The 2021 Share Option Scheme shows 4.96 million outstanding options with an adjusted exercise price of HKD 1.00. Full exercise would allow issuance of an equivalent 4.96 million new shares, with an additional 12.42 million shares available for future grants. No options were exercised in August.

• Convertible preference shares CPS outstanding total HKD 148.02 million, equivalent to 1.48 billion ordinary shares on a one-for-one conversion basis. The CPS can be converted at the holders’ discretion within a ten-year window ending November 2034. No conversions occurred during the period.

• No other corporate actions The company reported no new share issues, buy-backs, cancellations, warrant exercises, HDR activity, or other share movements in August 2026.

Sinopharm Tech’s unchanged capital base and maintained public-float ratio underscore a period of stability ahead of any future conversions of its sizeable preference-share pool.